(TheNewswire)
LONDON, ONTARIO – TheNewswire - January 21,2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), aclinical-stage regenerative medicine company announced today that Dr.Philip Toleikis, President and CEO has been invited to participate atthe Cell & Gene Virtual Meeting on the Med, and availableon-demand to attendees beginning Thursday, April 6 to 9. Dr. Toleikiswill deliver a corporate update on Sernova’s regenerative medicinetherapeutics platform including our US clinical cell therapy diabetesprogram as part of the 2021 Company Presentations at the Cell &Gene Meeting on the Med.
Sernova’s Corporate Update presentation will be available on-demandto attendees of the Virtual Cell & Gene Meeting on the Medthroughout the conference. For more details on Sernova’spresentation, please visit www.meetingonthemed.com .
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic solutionsusing a medical device (Cell Pouch™) and immune protectedtherapeutic cells/tissues (i.e., human donor cells, corrected humancells and stem cell-derived cells) to improve the treatment andquality of life of people with chronic metabolic diseases such asinsulin-dependent diabetes, blood disorders including hemophilia, andother diseases treated through cellular production of proteins orhormones missing or in short supply within the body. For moreinformation, please visit www.sernova.com .
ABOUT SERNOVA’S CELL POUCH™SYSTEM
The Cell Pouch™, as part of the Cell Pouch™ System, is a novel,proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device upon implantation is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins and hormones as required to treat disease. The CellPouch™, along with therapeutic cells, has been shown to providelong-term safety and efficacy in small and large animal models ofdiabetes and has been proven to provide a biologically compatibleenvironment for insulin-producing cells in humans in a Canadianfirst-in-human study. Sernova is currently conducting a Phase I/IIstudy at the University of Chicago.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are notrecitations of historical facts, may constitute “forward-lookingstatements” that involve various risks, uncertainties, andassumptions, including, without limitation, statements regarding theprospects, plans, and objectives of the Company. Wherever possible,but not always, words such as "expects", "plans","anticipates", "believes", "intends","estimates", "projects", "potential for"and similar expressions, or that events or conditions"will", "would", "may","could" or "should" occur are used to identifyforward-looking statements. These statements reflect management’sbeliefs with respect to future events and are based on informationcurrently available to management on the date such statements weremade. Many factors could cause Sernova’s actual results,performances or achievements to not be as anticipated, estimated orintended or to differ materially from those expressed or implied bythe forward-looking statements contained in this news release. Suchfactors could include, but are not limited to, the Company’s abilityto secure additional financing and licensing arrangements onreasonable terms, or at all; ability to conduct all requiredpreclinical and clinical studies for the Company’s Cell Pouch Systemand/or related technologies, including the timing and results of thosetrials; ability to obtain all necessary regulatory approvals, or on atimely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the Company’s quarterly and annual filings availableon www.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.